1,278
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Clinical features and outcomes of patients with antineutrophil cytoplasmic antibody-positive systemic lupus erythematosus

, , , , , & show all
Article: 2235431 | Received 08 Feb 2023, Accepted 06 Jul 2023, Published online: 20 Jul 2023

References

  • Davidson A. What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol. 2016;12(3):1–10. doi: 10.1038/nrrheum.2015.159.
  • Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol. 1989;135(5):921–930.
  • Windpessl M, Bettac EL, Gauckler P, et al. ANCA status or clinical phenotype - What counts more? Curr Rheumatol Rep. 2021;23(6):37. doi: 10.1007/s11926-021-01002-0.
  • Sen D, Isenberg DA. Antineutrophil cytoplasmic auto­antibodies in systemic lupus erythematosus. Lupus. 2003;12(9):651–658. doi: 10.1191/0961203303lu456rr.
  • Chin HJ, Ahn C, Lim CS, et al. Clinical implications of antineutrophil cytoplasmic antibody test in lupus nephritis. Am J Nephrol. 2000;20(1):57–63. doi: 10.1159/000013557.
  • Hill GS, Delahousse M, Nochy D, et al. Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int. 2005;68(5):2288–2297. doi: 10.1111/j.1523-1755.2005.00688.x.
  • Li C, Zhou M-L, Liang D-D, et al. Treatment and clinicopathological characteristics of lupus nephritis with anti-neutrophil cytoplasmic antibody positivity: a case-control study. BMJ Open. 2017;7(7):e015668. doi: 10.1136/bmjopen-2016-015668.
  • Nasr SH, D’Agati VD, Park H-R, et al. Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin J Am Soc Nephrol. 2008;3(3):682–690. doi: 10.2215/cjn.04391007.
  • Pan H-F, Fang X-H, Wu G-C, et al. Anti-neutrophil ­cytoplasmic antibodies in new-onset systemic lupus ­erythematosus and lupus nephritis. Inflammation. 2008;31(4):260–265. doi: 10.1007/s10753-008-9073-3.
  • Hochberg MC. Updating the American college of ­rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928.
  • Bossuyt X, Cohen Tervaert J-W, Arimura Y, et al. Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and ­microscopic polyangiitis. Nat Rev Rheumatol. 2017;13(11):683–692. doi: 10.1038/nrrheum.2017.140.
  • Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–S276. doi: 10.1016/j.kint.2021.05.021.
  • Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187–192. doi: 10.1002/art.1780370206.
  • Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi: 10.7326/0003-4819-150-9-200905050-00006.
  • Korbet SM, Lewis EJ, Schwartz MM, et al. Factors predictive of outcome in severe lupus nephritis. Lupus nephritis collaborative study group. Am J Kidney Dis. 2000;35(5):904–914. doi: 10.1016/s0272-6386(00)70262-9.
  • Sethi S, Haas M, Markowitz GS, et al. Mayo clinic/renal pathology society consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol. 2016;27(5):1278–1287. doi: 10.1681/ASN.2015060612.
  • Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi: 10.1080/00273171.2011.568786.
  • Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol. 2011;7(12):691–699. doi: 10.1038/nrrheum.2011.132.
  • Galeazzi M, et al. Anti-neutrophil cytoplasmic antibodies in 566 european patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European concerted action on the im­muno­genetics of SLE. Clin Exp Rheumatol. 1998;16(5):541–546.
  • Tamiya H, Tani K, Miyata J, et al. Defensins- and cathepsin G-ANCA in systemic lupus erythematosus. Rheumatol Int. 2006;27(2):147–152. doi: 10.1007/s00296-006-0173-9.
  • Gajic-Veljic M, Lekic B, Nikolic M, et al. Level and avidity of antineutrophil cytoplasmic antibodies specific to ­lactoferrin are useful biomarkers in systemic lupus erythematosus. Clin Rheumatol. 2022;41(3):709–720. doi: 10.1007/s10067-021-05926-x.
  • Wang Y, Huang X, Cai J, et al. Clinicopathologic characteristics and outcomes of lupus nephritis with antineutrophil cytoplasmic antibody: a retrospective study. Medicine (Baltimore). 2016;95(4):e2580. doi: 10.1097/MD.0000000000002580.
  • Wang S, Shang J, Xiao J, et al. Clinicopathologic characteristics and outcomes of lupus nephritis with positive antineutrophil cytoplasmic antibody. Ren Fail. 2020;42(1):244–254. doi: 10.1080/0886022X.2020.1735416.
  • Pyo JY, Jung SM, Song JJ, et al. ANCA positivity at the time of renal biopsy is associated with chronicity index of lupus nephritis. Rheumatol Int. 2019;39(5):879–884. doi: 10.1007/s00296-019-04263-2.
  • Turner-Stokes T, Wilson HR, Morreale M, et al. Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy. Kidney Int. 2017;92(5):1223–1231. doi: 10.1016/j.kint.2017.04.029.
  • Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol. 2006;17(5):1235–1242. doi: 10.1681/ASN.2005101048.
  • Yates M, Watts R. ANCA-associated vasculitis. Clin Med (Lond). 2017;17(1):60–64. doi: 10.7861/clinmedicine.17-1-60.
  • Chen M, Yu F, Zhang Y, et al. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine (Baltimore). 2008;87(4):203–209. doi: 10.1097/MD.0b013e31817c744b.
  • Li C, Wang J-J, Zhou M-L, et al. Differences in clinico-pathological characteristics and outcomes between proteinase 3-ANCA positivity and myeloperoxidase-ANCA positivity in lupus nephritis. Lupus. 2019;28(9):1111–1119. doi: 10.1177/0961203319861680.
  • Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century–a disease of older patients. Rheumatology (Oxford). 2005;44(4):495–501. doi: 10.1093/rheumatology/keh522.
  • Yang J, Liang D, Zhang H, et al. Long-term renal outcomes in a cohort of 1814 chinese patients with biopsy-proven lupus nephritis. Lupus. 2015;24(14):1468–1478. doi: 10.1177/0961203315593166.
  • Korbet SM, Schwartz MM, Evans J, et al. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18(1):244–254. doi: 10.1681/asn.2006090992.
  • Fussner LA, Hummel AM, Schroeder DR, et al. Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol. 2016;68(7):1700–1710. doi: 10.1002/art.39637.